| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 08/26/2004 | WO2004071416A2 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 08/26/2004 | WO2004071403A2 Coated particles and pharmaceutical dosage forms |
| 08/26/2004 | WO2004071402A2 STABLE PHARMACEUTICAL DOSAGE FORM COMPRISING HMG-CoA REDUCTASE INHIBITOR |
| 08/26/2004 | WO2004071399A2 Modulation of atp production or content in the hypothalamus |
| 08/26/2004 | WO2004071218A2 Preparation and food product comprising an active phytase |
| 08/26/2004 | WO2004060487A3 Composition for the treatment of hiv or aids |
| 08/26/2004 | WO2004050610A3 Modulators of melanocortin receptor |
| 08/26/2004 | WO2004014298B1 Composition and method for lowering cholesterol |
| 08/26/2004 | WO2003103585A3 Methods of treating angiogenesis, tumor growth, and metastasis |
| 08/26/2004 | WO2003070911A3 Rna interference mediated inhibition of type 1 insulin-like growth factor receptor (igf-1r) |
| 08/26/2004 | WO2003055440A3 Compositions and methods for the treatement of immune related diseases |
| 08/26/2004 | US20040167352 Clarifying by centrifugation or filtration; adsorption on nonionic resin; adsorption efficiency greatly increased in strong basicity of ph 10 to 13 |
| 08/26/2004 | US20040167341 Pyrrolidines as dipeptidyl peptidase inhibitors |
| 08/26/2004 | US20040167224 Nitrogen containing heterocyclic compounds and medicines containing the same |
| 08/26/2004 | US20040167219 Carnitine-magnesium hydroxycitrate |
| 08/26/2004 | US20040167183 Protein tyrosine phosphatase inhibitor; antidiabetic agents; hypotensive agents; cardiovascular disorders; inflammatory bowel disorders; antiulcer agents; wound healing agents; anticancer agents |
| 08/26/2004 | US20040167176 Tricyclic compounds useful as angiotensin II agonists |
| 08/26/2004 | US20040167172 Mixture of metformin and tyrosine phosphatase inhibitor |
| 08/26/2004 | US20040167160 Skin disorders; controlling cell differentiation; antidiabetic agents; cardiovascular disorders; anticancer agents; central nervous system disorders |
| 08/26/2004 | US20040167149 Aryl fused azapolycyclic compounds |
| 08/26/2004 | US20040167142 Pyrimidinone compounds |
| 08/26/2004 | US20040167141 Anticancer agents; antidiabetic agents; Alzheimer's disease |
| 08/26/2004 | US20040167138 Antiischemic agents; brain disorders |
| 08/26/2004 | US20040167137 Xanthine phosphodiesterase V inhibitors |
| 08/26/2004 | US20040167133 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 08/26/2004 | US20040167131 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| 08/26/2004 | US20040167129 Novel CB 1 receptor inverse agonists |
| 08/26/2004 | US20040167127 atherosclerosis; antiarthritic agents; antidiabetic agents; cardiovascular disorders; autoimmune diseases; multiple sclerosis; chronic obstructive pulmonary disease |
| 08/26/2004 | US20040167104 26,27-Homologated-20-epi-2-alkylidene-19-nor-vitamin D compounds |
| 08/26/2004 | US20040167081 Method for the prevention and treatment of cachexia and anorexia |
| 08/26/2004 | US20040167074 Therapeutic applications of mFLINT polypeptides |
| 08/26/2004 | US20040167064 Materials and methods relating for the treatment and diagnosis of pre-eclampsia |
| 08/26/2004 | US20040167034 Emulsion and dispersion formulations and method |
| 08/26/2004 | US20040166098 Insulin-secreting immortalized liver cell line modified by glucose sensitivity |
| 08/26/2004 | US20040166079 N-Lauroyl amino acid composition for slimming the human body |
| 08/26/2004 | CA2516269A1 Substituted 3-(benzoylureido)-thiophene derivatives, method for the production and use thereof |
| 08/26/2004 | CA2516118A1 Substituted n-arylheterocycles, method for production and use thereof as medicaments |
| 08/26/2004 | CA2515735A1 Substituted hexahydropyrazino(1,2-a)pyrimidin-4,7-dion derivatives, method for the production and use thereof as medicaments |
| 08/26/2004 | CA2515670A1 Phenylacetamides and their use as glucokinase modulators |
| 08/26/2004 | CA2515658A1 Medicinal composition |
| 08/26/2004 | CA2515607A1 Use of lupinus albus conglutin gamma for the treatment of type ii diabetes |
| 08/26/2004 | CA2514791A1 Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, method for the production and use thereof as medicaments |
| 08/26/2004 | CA2514720A1 Coated particles and pharmaceutical dosage forms |
| 08/25/2004 | EP1449529A1 Protein Kinase C Inhibitors |
| 08/25/2004 | EP1449518A1 Use of N-Octanoylaminoacids as cosmetic and pharmaceutical slimming agents |
| 08/25/2004 | EP1449517A1 Use of N-Lauroylaminoacids as cosmetic and pharmaceutical slimming agents |
| 08/25/2004 | EP1448993A2 Detection of autoantibodies reactive with pancreatic islet cell antigenic molecules and/or insulin |
| 08/25/2004 | EP1448566A2 Chemokine receptor antagonists and methods of use thereof |
| 08/25/2004 | EP1448564A2 Substituted indolizine-like compounds and methods of use |
| 08/25/2004 | EP1448562A1 Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors |
| 08/25/2004 | EP1448561A1 Beta 3 adrenergic agonists |
| 08/25/2004 | EP1448560A1 3-SUBSTITUTED OXINDOLE $g(b)3 AGONISTS |
| 08/25/2004 | EP1448559A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient |
| 08/25/2004 | EP1448558A1 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and pharmaceutical compositions comprising the same |
| 08/25/2004 | EP1448556A1 Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) |
| 08/25/2004 | EP1448553A1 N-heterocyclyl hydrazides as neurotrophic agents |
| 08/25/2004 | EP1448550A1 Nitrogenous tetrahydropyridyl-alkyl-heterocycles with tnf activity |
| 08/25/2004 | EP1448548A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5) |
| 08/25/2004 | EP1448546A1 Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake |
| 08/25/2004 | EP1448545A1 Nf-kb inhibitors |
| 08/25/2004 | EP1448542A1 6-hydroxy isoflavones, derivatives and medicaments involving same |
| 08/25/2004 | EP1448538A1 Peroxisome proliferator activated receptor alpha agonists |
| 08/25/2004 | EP1448535A1 Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 08/25/2004 | EP1448526A1 Piperidine-based mch antagonists for treatment of obesity and cns disorders |
| 08/25/2004 | EP1448523A1 Heterocyclic compounds and methods of use |
| 08/25/2004 | EP1448515A2 Compounds for treatment of inflammation, diabetes and related disorders |
| 08/25/2004 | EP1448513A1 Biphenyl-derivatives as p38-kinase inhibitors |
| 08/25/2004 | EP1448235A1 Pharmaceutical compositions of 5,7,14-triazatetracyclo 10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene |
| 08/25/2004 | EP1448226A1 Agonists and antagonists of prolixin for the treatment of metabolic disorders |
| 08/25/2004 | EP1448225A1 Agonists and antagonists of ryzn for the treatment of metabolic disorders |
| 08/25/2004 | EP1448222A1 Biphasic mixtures of glp-1 and insulin |
| 08/25/2004 | EP1448216A2 Methods for epitope-specific and cytokine/anticytokine combination immunotherapies for modulation of pathogenic immune responses in immune mediated diseases |
| 08/25/2004 | EP1448214A2 Ginger extract preparation |
| 08/25/2004 | EP1448213A2 Plant derived or derivable material with appetite suppressant activity |
| 08/25/2004 | EP1448205A2 Combinations for the treatment of immunoinflammatory disorders |
| 08/25/2004 | EP1448201A2 Use of n-(indolcarbonyl-)piperazine derivatives |
| 08/25/2004 | EP1448199A1 Benzimidazoles useful as protein kinase inhibitors |
| 08/25/2004 | EP1448195A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation |
| 08/25/2004 | EP1448193A1 Therapeutic compounds for treating dyslipidemic conditions |
| 08/25/2004 | EP1448190A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| 08/25/2004 | EP1448181A1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 08/25/2004 | EP1448180A1 Para-amino benzoic acids as integrin antagonists |
| 08/25/2004 | EP1448150A2 Treatment of hyperproliferative diseases using active vitamin d analogues |
| 08/25/2004 | EP1448089A2 Devices and methods for the restoration of a spinal disc |
| 08/25/2004 | EP1448064A1 Dosage form of aleuron |
| 08/25/2004 | EP1372641A4 Enteral formulation |
| 08/25/2004 | EP1360957A4 Vitamin/mineral complex |
| 08/25/2004 | EP1150977B1 Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
| 08/25/2004 | EP1087963B1 Inhibitors of glycogen synthase kinase 3 |
| 08/25/2004 | EP1086080B1 Diarylselenide compounds and their use in human or veterinary medicine and in cosmetics |
| 08/25/2004 | EP1025094B1 Substituted indan derivatives |
| 08/25/2004 | CN1524122A Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fatty liver in lipid biosynthesis |
| 08/25/2004 | CN1524090A Modified insulin with reduced immunogenicity |
| 08/25/2004 | CN1524082A Beta-amino tetrahydroimidazo (1,2-a) pyrazines and ahydrotrioazolo (4,3-a) pyrazines as dipeptidyl idase inhibitors for the treatment or prevention of diabetes |
| 08/25/2004 | CN1524079A Novel sulfamides and their use as endothelin receptor antagonists |
| 08/25/2004 | CN1524078A Antagonists of mcp-1 function and methods of use thereof |
| 08/25/2004 | CN1524073A Crystalline forms of 'r-(r*,r*)-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) |
| 08/25/2004 | CN1524002A Treatment or prophylaxis of insulin-producing cell graft rejection |
| 08/25/2004 | CN1523992A Compositions and methods for treating amyloidosis |
| 08/25/2004 | CN1523989A Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |